Sernova Corp

About Sernova Corp

Sernova Corp is a biotechnology company located in the Old Masonville area of London, Ontario. The company focuses on developing regenerative therapeutic solutions for individuals living with type 1 diabetes (T1D) and other chronic diseases caused by deficiencies in necessary hormones, factors, and proteins. The company offers a unique approach to chronic disease treatment by harnessing the Cell Pouch bio-hybrid organ and regenerative therapeutic cell technology. Their platform includes a clinically validated, implantable, and retrievable device designed to support islet cell survival, engraftment, and function. Sernova is also involved in a merger with Seraxis Holdings, Inc. to create BetaNova Biotherapeutics, a company that will combine Sernova's bio-hybrid organ with Seraxis' stem cell-derived pancreatic islet cells and in-house cGMP manufacturing. Their pipeline includes the SR-02 allogeneic islet cell therapy and the SR-03 next-generation gene-edited islet cell therapy. Sernova describes its mission as correcting the underlying causes of chronic diseases to give patients their lives back. The company emphasizes its commitment to providing resources for patients to understand and manage their conditions, including access to clinical trials. The company's clinical foundation includes over 30 years of cumulative patient safety data supporting its platform. Jonathan Rigby serves as the President and CEO of Sernova.